Cargando…
738. Potent In Vitro activity of Rezafungin (RZF) Against Aspergillus Clinical Isolates Recovered From Lung Transplant Patients Who Have Received ≥3 Months of Triazole Prophylaxis
BACKGROUND: Emergence of azole resistance globally among Aspergillus species has major one health implications for humans and agriculture. At our center, isavuconazole (ISA), posaconazole (POS) and voriconazole (VOR) have been used as antifungal prophylaxis for at least 3 months or as pre-emptive th...
Autores principales: | Driscoll, Eileen, Clancy, Cornelius J, Nguyen, Minh-Hong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811278/ http://dx.doi.org/10.1093/ofid/ofz360.806 |
Ejemplares similares
-
1390. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Rezafungin (RZF) Dose Selection in Treatment of Candida
por: Lakota, Elizabeth A, et al.
Publicado: (2018) -
357. Aspergillus Isolates Remain Largely Susceptible to Azoles and Other Antifungals at a Large Transplant Program Using Azole Prophylaxis
por: Driscoll, Eileen, et al.
Publicado: (2018) -
Extended-Interval Dosing of Rezafungin against Azole-Resistant Aspergillus fumigatus
por: Wiederhold, Nathan P., et al.
Publicado: (2019) -
Rezafungin treatment in mouse models of invasive candidiasis and aspergillosis: Insights on the PK/PD pharmacometrics of rezafungin efficacy
por: Miesel, Lynn, et al.
Publicado: (2019) -
Mutations in RZF1, a zinc-finger protein, reduce magnesium uptake in roots and translocation to shoots in rice
por: Kobayashi, Natsuko I, et al.
Publicado: (2023)